RSS   Newsletter   Contact   Advertise with us

Silence Therapeutics appoints David Ellam as CFO

Share on Twitter Share on LinkedIn
Staff writer | London, United Kingdom | May 25, 2016
Silence TherapeuticsMay 25, 2016, London, United Kingdom - Silence Therapeutics, a biotechnology company, announced that David Ellam will become chief financial officer and a director from July 18, 2016.
Mr. Ellam has previously occupied several senior finance roles within both US & UK publicly owned life science companies, most recently as Senior EUMEA Finance Director at BioMarin Pharmaceuticals Inc. from 2010 to 2016, as CFO of Plethora Solutions Plc (2008-2009) and as Group Financial Controller at Ark Therapeutics Plc (2001-2008).

Mr. Ellam is a Chartered Accountant.


 LATEST MOVES FROM United Kingdom 


MORE INSIDE POST